REVANCE THERAPEUTICS LTD
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 597
- Market Cap
- $685.5M
- Website
- http://www.revance.com
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 247
- Registration Number
- NCT01776606
- Locations
- 🇺🇸
Dermatology Research Institute, Coral Gables, Florida, United States
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT01124552
- Locations
- 🇺🇸
Dermatology Research Institute, LLC, Coral Gables, Florida, United States
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01124565
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸Total Skin & Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸Skin Specialists, PC, Omaha, Nebraska, United States
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
- Conditions
- Interventions
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01064518
- Locations
- 🇺🇸
Dermatology Research Institute, LLC, Coral Gables, Florida, United States
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
- Conditions
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00968942
- Locations
- 🇺🇸
Dermatology Research Institute, LLC., Coral Gables, Florida, United States
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
- Conditions
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT00968825
- Locations
- 🇺🇸
RGG, Inc, San Francisco, California, United States
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00907387
- Locations
- 🇺🇸
Dermatology Research Institute, LLC, Coral Gables, Florida, United States
🇺🇸Total Skin & Beauty Dermatology Center, Birmingham, Alabama, United States
🇺🇸Richard G. Glogau, Inc., San Francisco, California, United States
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
- Conditions
- Interventions
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00888914
- Locations
- 🇺🇸
Richard G. Glogau, MD, San Francisco, California, United States
🇺🇸Aesthetic Plastic Surgery, New York City, New York, United States
🇺🇸Head and Neck Surgical Group, New York City, New York, United States
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
- Conditions
- Interventions
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Revance Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00884234
- Locations
- 🇺🇸
Suzanne Bruce & Associates / The Center for Skin Research, Houston, Texas, United States